Alan Paciorek
Overview
Explore the profile of Alan Paciorek including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
490
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Wang S, Whitman J, Paciorek A, Le B, Nakakura E, Behr S, et al.
J Neuroendocrinol
. 2023 Apr;
35(4):e13260.
PMID: 37002881
Refined risk stratification for gastroenteropancreatic neuroendocrine tumors (GEP-NETs) has the potential to improve comparisons of study populations across clinical trials and facilitate drug development. Tumor growth rate (TGR) is a...
12.
Savoie M, Paciorek A, Van Loon K, Anwar M, Atreya C, Johnson P, et al.
J Sex Med
. 2023 Feb;
20(4):439-446.
PMID: 36805959
Background: Women diagnosed with colorectal cancer (CRC) or anal squamous cell carcinoma (ASCC) are at high risk of sexual dysfunction after treatment, yet little is known about recovery and risk...
13.
Weng X, Zhong L, Xiang P, Li Y, Paciorek A, Dong L, et al.
Eur J Cancer Care (Engl)
. 2022 Oct;
31(6):e13740.
PMID: 36239065
Objective: We evaluate cost-effectiveness of primary treatments for localised prostate cancer by uniquely combining prospectively collected real-world outcomes and costs from UCSF Cancer of Prostate Strategic Urologic Research Endeavor (CaPSURE™)....
14.
Morgan J, DeBoer R, Bigirimana J, Nguyen C, Ruhangaza D, Paciorek A, et al.
JCO Glob Oncol
. 2022 Jul;
8:e2200131.
PMID: 35839427
Purpose: In describing our ten-year experience with treating chronic myeloid leukemia (CML) as part of the Glivec Patient Assistance Program (GIPAP) in rural Rwanda, we evaluate (1) patient characteristics and...
15.
Kwon D, Paciorek A, Zhang L, Borno H, Bucknor M, Small E, et al.
Urol Oncol
. 2022 Jun;
40(8):379.e17-379.e24.
PMID: 35750560
Background: Skeletal-related events (SREs) from bone metastases disease carry significant morbidity in men with metastatic castration resistant prostate cancer (mCRPC). The differential risk of SREs among patients receiving abiraterone acetate...
16.
Chan H, Van Loon K, Kenfield S, Chan J, Mitchell E, Zhang L, et al.
Support Care Cancer
. 2022 Feb;
30(5):4557-4564.
PMID: 35119520
Purpose: There are over 1.3 million colorectal cancer (CRC) survivors in the USA, many of whom report lower health-related quality of life (HRQoL) years after treatment. This study aimed to...
17.
Buckle G, Mmbaga E, Paciorek A, Akoko L, Deardorff K, Mgisha W, et al.
JCO Glob Oncol
. 2022 Feb;
8:e2100256.
PMID: 35113655
Purpose: Eastern Africa is one of several regions affected by high incidence rates of esophageal squamous cell carcinoma (ESCC). A unique epidemiologic feature of ESCC in Eastern Africa is the...
18.
Buckle G, Mrema A, Mwachiro M, Ringo Y, Selekwa M, Mulima G, et al.
BMC Cancer
. 2022 Jan;
22(1):82.
PMID: 35045815
Background: Esophageal squamous cell carcinoma (ESCC) is a major cause of cancer morbidity and mortality in Eastern Africa. The majority of patients with ESCC in Eastern Africa present with advanced...
19.
DeBoer R, Umutoni V, Bazzett-Matabele L, Katznelson E, Nguyen C, Umwizerwa A, et al.
Gynecol Oncol
. 2021 Dec;
164(2):370-378.
PMID: 34916066
Objective: Most cervical cancer cases and deaths occur in low- and middle-income countries, yet clinical research from these contexts is significantly underrepresented. We aimed to describe the treatment quality, resource-driven...
20.
Burns S, Vella M, Paciorek A, Zhang L, Atreya C, Feng M, et al.
Am J Clin Oncol
. 2021 Dec;
45(1):22-27.
PMID: 34864778
Introduction: There are no formal guidelines for the management of patients with primary gastrointestinal (GI) cancers who have lung-exclusive or lung-predominant metastases. We performed a retrospective analysis to evaluate host...